Narcan Nasal Spray is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.

Emergent BioSolutions (NYSE:EBS) said the U.S. Food and Drug Administration has approved a supplemental New Drug Application ...

Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis GAITHERSBURG, Md., July 02, ...

Naloxone helped reverse nearly 9,500 overdoses in Pennsylvania last year, according to an annual report on the state’s ...

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid ...

Walgreens announced this week that it plans to stock all of its stores across the U.S. with Narcan as the nation's opioid epidemic reaches new levels. The medication, which is administered via nasal ...

(The Hill) – Emergent BioSolutions Inc., the maker of narcotic overdose treatment Narcan, said on Tuesday that the Food and Drug Administration (FDA) has accepted its application to grant priority ...

The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent ...

Emergent BioSolutions signed a $65 million contract to supply NARCAN® Nasal Spray to Ontario's Naloxone Program for opioid overdose prevention. Emergent BioSolutions Inc. has announced a three-year ...

Public health agencies faced a chaotic few days after the Trump administration canceled more than $2 billion in grants for ...